Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

REVEAL Study: Clinical Implications

January 12th 2024

Expert oncologists discuss the REVEAL study and provide their thoughts on these data and the impact in clinical practice.

Polycythemia Vera: Assessing Risk and Genetic Testing

January 12th 2024

Experts discuss the optimal strategy for NGS testing, which alterations to test for and how to assess for risk when diagnosing and managing patients with polycythemia vera (PV).

Dr Mascarenhas on the Potential Utility of Selinexor Plus Ruxolitinib in Myelofibrosis

January 11th 2024

John Mascarenhas, MD, discusses the potential advantages of utilizing selinexor with ruxolitinib in patients with JAK inhibitor–naive myelofibrosis.

Dr Kuykendall on the Efficacy of Pelabresib Plus Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis

January 9th 2024

Andrew Kuykendall, MD, discusses the efficacy of pelabresib plus ruxolitinib in patients with JAK inhibitor–naive myelofibrosis.

Research Developments Provide Clarity and Raise Further Questions in Myeloma, Myelofibrosis, DLBCL, and MDS

January 5th 2024

Sikander Ailawadhi, MD, discusses characteristics of myelofibrosis that influence decisions between JAK inhibitors, highlights differences between bispecific antibodies to consider when managing diffuse large B-cell lymphoma, and more.

Dr Sallman on the Rationale For Investigating Fedratinib in MDS/MPN Overlap Syndromes

January 4th 2024

David A. Sallman, MD, discusses the rationale for conducting a phase 2, multi-institutional, investigator-initiated clinical trial on the use of fedratinib in patients with myelodysplastic syndromes/myeloproliferative neoplasm overlap syndromes and chronic neutrophilic leukemia.

Diagnosing Polycythemia Vera (PV)

December 19th 2023

Experts explain how polycythemia vera is diagnosed and the typical symptoms a patient may present with.

TP-3654 Demonstrates Favorable Tolerability, Early Clinical Activity in R/R Myelofibrosis

December 19th 2023

The oral selective PIM1 kinase inhibitor TP-3654 appeared to be well tolerated and to show early signals of spleen volume reduction, symptom improvement, and correlating cytokine reductions in patients with relapsed or refractory myelofibrosis, according to preliminary data.

SRSF2 Mutations Lead to Lessened Frequency of Polycythemia in Preclinical MPN Models

December 13th 2023

The presence of mutated SRSF2 in knock-in mouse models of JAK2 V617F–driven myeloproliferative neoplasms reduced the rate of polycythemia and hampered hematopoietic progenitor functions.

Taking Trial Data to the Clinic in MPN and CLL From ASH 2023: Drs Rogers, Brown, and Shammo

December 13th 2023

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASH Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Dr Rampal on Findings From the MANIFEST-2 Trial in JAK Inhibitor–Naive Myelofibrosis

December 12th 2023

Raajit K. Rampal, MD, PhD, discusses findings from the phase 3 MANIFEST-2 trial investigating pelabresib in combination with ruxolitinib for JAK inhibitor–naive patients with myelofibrosis.

Pelabresib/Ruxolitinib Combo Improves Splenomegaly, TSS in JAK Inhibitor–Naive Myelofibrosis

December 11th 2023

Pelabresib plus ruxolitinib demonstrated a 35% or greater reduction in spleen volume and trended toward reducing mean absolute total symptom score (TSS) as well as improving TSS reduction by 50% at 24 weeks in patients with JAK inhibitor–naive myelofibrosis.

Oral DEC-C Treatment Is Feasible and Comparable With IV/SC HMA Outcomes in MDS

December 10th 2023

Oral decitabine/cedazuridine and parenteral hypomethylating agents were associated with similar levels of comorbidities and disease burden in patients with myelodysplastic syndrome.

Adding Navitoclax to Ruxolitinib Doubles Spleen Volume Reductions for Myelofibrosis

December 10th 2023

Up-front treatment with navitoclax plus ruxolitinib significantly reduced spleen volume by 35% or more at week 24 vs ruxolitinib plus placebo in patients with myelofibrosis; however, a significant difference was not observed in total symptom score v. 4.0 between the arms, according to data from the phase 3 TRANSFORM-1 study.

Orca-T Shows High Survival Rates in Intermediate-/High-Risk Myelodysplastic Syndrome

December 10th 2023

The high-precision cell therapy Orca-T demonstrated high rates of relapse-free survival, overall survival, and graft-vs-host disease RFS at 1 year, as well as a low incidence of GVHD in patients with intermediate- to high-risk myelodysplastic syndrome.

AI Algorithm Effectively Differentiates Between pre-PMF/ET

December 9th 2023

A machine learning, artificial intelligence algorithm analyzing diagnostic bone marrow biopsy digital whole-slide images was able to effectively differentiate with 92.3% accuracy between prefibrotic primary myelofibrosis and essential thrombocythemia.

Dr Zeidan on Classification and Treatment Updates in MDS

December 1st 2023

Amer Zeidan, MBBS, discusses classification and treatment updates for patients with myelodysplastic syndrome.

Dr Kremyanskaya on the Use of Cytoreductive Measures in PV and ET

December 1st 2023

Marina Kremyanskaya, MD, PhD, discusses disease and patient characteristics that influence the choice between hydroxyurea and interferon therapy for patients with polycythemia vera or essential thrombocythemia.

Pelabresib Plus Ruxolitinib Improves Spleen Volume Reduction in JAK Inhibitor-Naive Myelofibrosis

November 21st 2023

Treatment with the combination of pelabresib and ruxolitinib led to a statistically significant and clinically meaningful improvement in spleen volume reduction vs placebo plus ruxolitinib in patients with JAK inhibitor-naive myelofibrosis, meeting the primary end point of the phase 3 MANIFEST-2 trial.

FDA Approval Insights: Ivosidenib in R/R IDH1+ Myelodysplastic Syndrome

November 20th 2023

Dr DiNardo discusses the the FDA approval of ivosidenib for patients with relapsed/refractory IDH1-mutant myelodysplastic syndromes, the unique mechanism of action of ivosidenib, and key efficacy and safety findings from the AG120-C-001 trial.